Clinical Trial Update: A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase II study evaluating 250-mg ZD1839 (gefitinib) as monotherapy in recurrent/metastatic head and neck squamous cell carcinoma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• ZD1839 (Gefitinib)

Snippet

Sponsor: University of Chicago | Conditions: Head and Neck Cancer | Phase 2 | Status: COMPLETED